Lecture 17: Alzheimers Flashcards
Alzheimer’s vs Dementia?
What is the difference?
Alzheimer’s disease is the most common CAUSE of dementia (general intellectual deterioration)
Alzheimer’s age ranges, common ages to develop etc
Appears in people as young as 40, but chances of development increase with age.
10% of people over 65 y/o suffer from it, 35% over 85.
What is meant by alz as a progressive disease?
Progressive disease - gets worse with time.
- Early stages are characterised by selective memory decline
- Intermediate stages marked by confusion, irritability, anxiety, deterioration of speech etc
- In the advanced stages the patient deteriorates to the point where swallowing and bladder control become difficult.
The disease is terminal
Problems diagnosing alz…
Because Alzheimer’s isn’t the only cause of dementia, it cannot be diagnosed based solely on behavioural symptoms, it is definitively diagnosed via autopsy
Defining characteristics of the disease…
The two defining characteristics of the disease are neurofibrillary tangles and amyloid plaques. As well as substantial neuron loss.
Neurofibrillary tangles – thread-like tangles of protein in the neural cytoplasm
Amyloid plaques – clumps of scar tissue composed of degenerating neurons and a protein called amyloid (present in normal brains in very small amounts)
Neurofibrillary tangles
thread-like tangles of protein in the neural cytoplasm
Amyloid plaques
clumps of scar tissue composed of degenerating neurons and a protein called amyloid (present in normal brains in very small amounts)
Distribution of amyloid plaques and neuro tangles
Although neuron loss, neurofibrillary tangles and amyloid plaques occur throughout the brains of alz. patients, they are more prevalent in certain areas e.g. prevalent in medial temporal lobe structures like the entorhinal cortex, amygdala and hippocampus (areas involved in memory).
Also prevalent in the inferior temporal cortex, posterior parietal cortex and prefrontal cortex – all areas that mediate complex cognitive functions.
Genetic component of Alzheimer’s disease…
- Alz. disease has a major genetic component.
- People with a victim of it in their immediate family have a 50% chance of developing the disease if they survive into their 80s.
- Accordingly, lots of research has focused on early onset familial forms of the disease.
- Several gene mutations have been found to be associated with early onset alz.
A cure?
There is currently no cure. The massive research effort into finding a cure is fuelled by two things: the severity of the problem and the fact that a major advance seems feasible (as the disease is a disease of old age, the number of cases could be halved by a treatment that would slow it’s progress by 5 years)
What’s stopping the development of a cure?
The major problem affecting a breakthrough is the fact that it’s not clear which symptom is primary. The amyloid hypothesis holds that the amyloid plaques are the primary symptom, others believe it’s the neurofibrillary tangles and others support other contenders.
Amyloid hypothesis
The amyloid hypothesis holds that the amyloid plaques are the primary symptom
The main support for the amyloid hypothesis is from genetic analysis of families with the early onset Alzheimer’s disease.
The studies have identified three different gene mutation that cause early onset alz. and all three influence the synthesis of amyloid. Amyloid is toxic to neurons that have been artificially maintained in tissue cultures.
First efforts to develop a cure…
The first efforts to develop treatments focused on the perceived declines in acetylcholine levels, were among the earliest neurochemical changes appearing in patients.
Cholinergic agonists are still sometimes prescribed, except for a few minor benefits early on in the disorder, they have proved ineffective.
Immunotherapeutic approach to a cure…
Arguably, the most promising of the current developing treatments is the immunotherapeutic approach.
This approach has used an amyloid vaccine to reduce plaque deposits and improve performance on memory tasks in a transgenetic mouse model of Alzheimer’s disease
One study of an anti-amyloid antibody in the mouse model found that the health of nearby neurons improved once amyloid plaques had been cleared from the area – supporting the amyloid hypothesis.
Human trials of immunotherapeutic agents have been mixed. Some therapeutic effects have been observed, but some patients have experienced dangerous brain inflammation.
Transgenetic mouse model of Alzheimer’s disease
What are transgenetic animals?
Transgenetic animals are animals into which the genes of another species have been introduced.